Refractory myasthenia gravis
Myasthenia gravis (MG) is an autoimmune condition in which the body mistakenly attacks itself. In MG, the way nerves and muscles communicate is affected. MG is treated with different …
Objective: To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs …
The primary efficacy endpoint was the change of the MG-ADL score from baseline to week 26. Ravulizumab was more effective than placebo in improving MG-ADL (−3.1 vs 1.4) …Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. Methods: We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with rituximab. ...Clinical status and severity were determined by the recommendations of the Myasthenia Gravis Foundation of America. Results: Of 1388 patients with MG, 12 (0.9%) patients received eculizumab. A total of 11 patients who were anti-acetylcholine receptor antibody-positive with refractory gMG (M:F = 3:8) completed the 26-week treatment with eculizumab.Vissing J, O’Brien F, Wang JJ, et al. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 REGAIN study.Here we report a case of mixed connective tissue disease, with features of systemic lupus erythematosus and systemic sclerosis developing in a patient 10 years post thymectomy for myasthenia gravis. The patient developed acute cutaneous lupus, Raynaud's with digital ulcers, arthritis and lymphopenia. Her myasthenia continued to be resistant to ...
Mar 1, 2019 · Vissing J, O’Brien F, Wang JJ, et al. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 REGAIN study. Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive to conventional therapy and display high disease severity, which calls for further ... Myasthenia Gravis (MG) is a rare autoimmune disorder that targets the neuromuscular junction (NMJ). It is caused by B-cell activation with subsequent production of autoantibodies targeting different proteins of the postsynaptic endplate. About 80–90% of patients have antibodies directed against the nicotinic acetylcholine receptor (AChR ...The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG). Myasthenia gravis (MG) often affects women of child-bearing potential.Background: Life-threatening myasthenic crisis (MC) occurs in 10–20% of the patients with myasthenia gravis (MG). It is important to identify the predictors of progression to MC and prognosis in the patients with MG with acute exacerbations.Objective: This study aimed to explore the predictors of progression to MC in the patients with MG with acute onset of dyspnea and their short-term and ...
A total of 512 patients fulfilled the clinical and diagnostic criteria of myasthenia gravis of which 76 patients met the diagnostic certainty for refractory myasthenia gravis and were evaluated.Side effects, which usually are mild, can include chills, dizziness, headaches and fluid retention. Monoclonal antibody. Rituximab (Rituxan) and eculizumab (Soliris) are medicines given by vein for myasthenia gravis. These medicines are usually used when other treatments don't work. They can have serious side effects.A prospective open label multicentre study of 34 patients with refractory generalised myasthenia gravis treated with Zytux (a rituximab biosimilar) showed reduced disease activity and improved quality of life.13 Although these data are encouraging, the BeatMG (B Cell Targeted Treatment in Myasthenia Gravis) study, a phase 2 randomised ... Myasthenia gravis (MG) is an autoantibody-mediated disease that compromises the acetylcholine receptors or associated structures of the postsynaptic membrane of the neuromuscular junction. This leads to impaired neuromuscular transmission and subsequent fluctuating fatigability and weakness of ocular, bulbar, and limb skeletal muscles.Myasthenia gravis (MG) is a rare autoimmune disease that affects around 11–32 people per 100,000. 1–3 Because of improved recognition and diagnosis, its incidence is increasing. 4,5 The
Sara bonner.
7 Mantegazza R and Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Therapeutic Advances in Neurological Disorders; 11:1756285617749134. 8 Schneider-Gold C, Hagenacker T, Melzer N et al. Understanding the burden of refractory myasthenia gravis. Therapeutic Advances in Neurological …Furthermore, refractory patients may be at greater risk of crises throughout the disease course than previous studies have suggested. Muscle Nerve, 2018. Keywords: burden; myasthenia gravis; myasthenic crises; myasthenic exacerbations; refractory; utilization.Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. Most patients with MG are successfully treated with acetylcholinesterase inhibitors, corticosteroids, and/or steroid sparing agents such as azathioprine and mycophenolate mofetil.Jul 22, 2020 · Objective. To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis across four domains ...
Introduction: This study assessed the clinical burden of refractory myasthenia gravis (MG), relative to nonrefractory MG. Methods: Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases. Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. Methods: We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with ...Introduction Myasthenia gravis (MG) is a rare, debilitating, chronic disorder caused by the production of pathogenic immunoglobulin G autoantibodies against the neuromuscular junction. A lack of real-world studies in rare diseases reflects a relatively limited understanding of the significant unmet needs and burden of disease for patients. We aimed to provide comprehensive real-world insights ...Two potentially related microRNAs (miRNAs; miR-150-5p and miR-146a-5p) were examined after low-dose rituximab (RTX) treatment in patients with acetylcholine receptor antibody (AChR)-positive refractory myasthenia gravis (MG). In this prospective, open-label, and self-controlled pilot trial, 12 AChR- …Myasthenia Gravis (QMG) score,25 the revised 15-item Myasthenia Gravis Quality of Life (MG-QOL15r) question-naire,26 and the Neurological Quality of Life (Neuro-QoL) Fatigue subscale.27 A copy of each measure is provided in the Supplementary Appendix (pages 24–28). The MG-ADL is an 8-item survey of patient-reported MG symptomJun 13, 2013 · Background: A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group.Objective: The aim ... Our patient has had a refractory course with respect to myasthenia gravis. Other options for treatment of refractory myasthenia gravis include rituximab, high-dose cyclophosphamide and eculizumab . Given our patient’s progression of both autoimmune diseases, we explored the possibility of hematopoietic stem cell transplant (HSCT).
Myasthenia gravis (MG) is an autoantibody-mediated neuromuscular junction disorder involving the acetylcholine receptors on the motor endplate. The safety and response to high-dose chemotherapy (HDIT) and autologous hematopoietic cell transplantation (HCT) were assessed in a patient with severe refractory MG.
Introduction/aims: Up to 25% of patients with myasthenia gravis (MG) have refractory disease despite trials of multiple immunosuppressants. Several case series describe acetylcholine receptor antibody-positive (AChR) MG patients treated with autologous hematopoietic stem cell transplant (HSCT). SYSTEMATIC REVIEW article. Front. Neurol., 13 October 2021. Sec. Neuromuscular Disorders and Peripheral Neuropathies. Volume 12 - 2021 | …Abstract. Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. Treatment-refractory MG and long-term toxicities of the medications have been major concerns with the conventional therapies.A modified treatment algorithm for MG is proposed: patients who have disease that fails to respond to the stepwise approach to therapy, are treatment intolerant, or who require chronic rescue measures despite ongoing therapy, should be considered treatment refractory and emerging therapies should be considered.Jan 1, 2021 · Patients Who Achieved Myasthenia Gravis Foundation of America Post-intervention Status of Improved or Minimal Manifestations at REGAIN (Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia Gravis) Weeks 4, 12, and 26, and Open-Label Study Weeks 26, 52, 78, 104, and 130 26 июл. 2018 г. ... Several retrospective case series have suggested rituximab (RTX) might improve patients with refractory Myasthenia Gravis (MG). This study ...The primary outcome measure was the occurrence of treatment-refractory MG. We defined treatment-refractory myasthenia gravis at the earliest 2 years after diagnosis as soon as the following conditions were met: 1. Persistent moderate to severe myasthenic symptoms (i.e., ≥ MGFA class III) for the last 12 months OR. 2.
Tracy weather underground.
What are induced earthquakes.
Background Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but also psychological and social well-being are limited. We aim to describe the burden of disease in MG including sociodemographic, economical, psychosocial as well as clinical aspects, to compare health-related quality of life (HRQoL) of patients with MG to …A prospective open label multicentre study of 34 patients with refractory generalised myasthenia gravis treated with Zytux (a rituximab biosimilar) showed reduced disease activity and improved quality of life.13 Although these data are encouraging, the BeatMG (B Cell Targeted Treatment in Myasthenia Gravis) study, a phase 2 randomised ... To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods. This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients …Oct 13, 2016 · Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab Abstract. Introduction: Myasthenia gravis (MG) is an antibody mediated autoimmune neuromuscular disorder characterized... Introduction. Myasthenia gravis (MG) is a relatively rare antibody-mediated neurologic ... May 9, 2022 · Background Patients with generalized myasthenia gravis (MG) often experience debilitating exacerbations, with the possibility of life-threatening respiratory crises requiring hospitalization. Long-term longitudinal studies are needed to understand the burden of MG, including in patients whose disease is refractory to conventional treatment. Methods A retrospective, longitudinal, cohort study ... Introduction. Myasthenia gravis is an autoimmune disease of the neuromuscular junction with a prevalence of around 16 per 100,000 [].Patients are grouped according to the age at onset, presence of a specific antibody, thymus pathology, and distribution of symptoms [].The majority of patients (approximately 80%) have antibodies …Patients with refractory generalised myasthenia gravis, representing approximately 10–15% of all patients with myasthenia gravis, do not respond to long-term treatment with corticosteroids or multiple steroid-sparing immunosuppressive treatments, or they have intolerable side-effects to these therapies or require ongoing treatment with either ...View/Print PDF. Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder that causes skeletal muscle fatigable weakness and is the most common neuromuscular disorder. 1 Management of MG is based on clinical severity of symptoms, type of autoantibody involved, age, comorbidities, and the presence of thymoma. All the above-mentioned favorable outcomes of rituximab in refractory myasthenia gravis patients have widened the options for treatment of refractory myasthenia gravis; they have also demonstrated that RTX could improve patients' quality of life by decreasing dose-related adverse effects and sustaining remission [10,12-17]. Even though RMG ...Traditionally, patients with myasthenia gravis have been treated with pyridostigmine, corticosteroids, immunosuppressants (eg, azathioprine and mycophenolate mofetil), …What is generalized Myasthenia Gravis (gMG)? Myasthenia gravis (MG) is a debilitating, chronic, and progressive autoimmune neuromuscular disease that can occur at any age but most commonly begins for women before the age of 40 and men after the age of 60. 1-4 It typically begins with weakness in the muscles that control the movements of the eyes and eyelids, and often progresses to the more ...Myasthenia gravis (MG) is a rare autoimmune disease characterised by antibody-mediated interference with neuromuscular transmission at the neuromuscular junction [].MG is classed as a rare disease, and its prevalence is estimated to be about 1–2 per 10,000 people [].However, reported incidence rates are increasing, partly due to … ….
The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG). Myasthenia gravis (MG) often affects women of child-bearing potential.Jan 18, 2018 · The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half century, including substantial reductions in mortality and morbidity. However, approximately 10% of patients fails to respond adequately to current therapies and are considered treatment refractory, or treatment intolerant, and up to 80% have ... A prospective open label multicentre study of 34 patients with refractory generalised myasthenia gravis treated with Zytux (a rituximab biosimilar) showed reduced disease activity and improved quality of life.13 Although these data are encouraging, the BeatMG (B Cell Targeted Treatment in Myasthenia Gravis) study, a phase 2 randomised ... Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating autoimmune disease. Activation of the complement system by autoantibodies against the postsynaptic acetylcholine receptor (AChR) leads to destruction of the postsynaptic membrane and disruption of neuromuscular transmission. This trial evaluated ravulizumab, a long-acting ...Aug 29, 2023 · refractory myasthenia gravis, quality of life, acetylcholine receptor, muscle specific kinase, thymectomy, eculizumab, rituximab, tacrolimus, cyclophosphamide Abstract Refractory myasthenia gravis identifies the group of patients that have inadequate symptom control and persistent muscle weakness and fatigability despite the use of multiple ... Importance Some patients with myasthenia gravis (MG) do not respond to conventional treatment and have severe or life-threatening symptoms. Alternate and emerging therapies have not yet proved consistently or durably effective. Autologous hematopoietic stem cell transplant (HSCT) has been effective in treating other severe autoimmune neurologic conditions and may …The humanized monoclonal antibody eculizumab (Soliris ®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan.It is …Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment. Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the mu...Abstract. Objective: To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods: This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES).Introduction Patients with generalized myasthenia gravis (gMG) experience functional impairment due to MG symptoms. This study aimed to assess, from the patient perspective, the symptoms, impacts, and treatment goals of individuals diagnosed with gMG. Methods Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States ... Refractory myasthenia gravis, Introduction. Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. It is caused by antibody mediated attacks on the nicotinic acetylcholine receptors (AChR), muscle specific tyrosine kinase (MuSK), and various other novel targets like anti-lipoprotein-related protein 4 (LRP4). 1,2 It is treated symptomatically with acetylcholinesterase inhibitors while the ..., In these cases, individualized treatment strategies involving other immunomodulatory therapies, such as eculizumab or rituximab, may be considered., In October 2020, the CADTH Canadian Drug Expert Committee assessed the use of eculizumab for the treatment of adult patients with refractory generalized myasthenia gravis and gave a conditional ..., Patients Who Achieved Myasthenia Gravis Foundation of America Post-intervention Status of Improved or Minimal Manifestations at REGAIN (Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia Gravis) Weeks 4, 12, and 26, and Open-Label Study Weeks 26, 52, 78, 104, and 130, Introduction: Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients. However, 10%-20% of patients present refractory MG, with frequent relapses and significant functional limitations. Patients and methods: Patients with refractory MG were selected from a cohort of patients diagnosed …, In previous work, we have used patient‐reported data from the MG Patient Registry developed by the Myasthenia Gravis Foundation of America (MGFA) to compare health‐care resource utilization in patients with refractory MG to that in patients with nonrefractory MG.4 Here, we use the same data set to explore employment status and absences from ..., Symptoms The following symptoms are commonly associated with myasthenia gravis: Weakness of the eye muscles (ocular myasthenia) Drooping of one or both eyelids (ptosis) Blurred or double vision (diplopia) Changes in facial expressions Difficulty swallowing Shortness of breath Impaired speech (dysarthria), Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder that causes skeletal muscle fatigable weakness and is the most common neuromuscular disorder. 1 Management of MG is based on clinical severity of symptoms, type of autoantibody involved, age, comorbidities, and the presence of thymoma. Conventional treatment may be ..., Introduction: Approximately 10-20% of patients WITH myasthenia gravis (MG) are refractory to conventional immunotherapies. The purpose of this study was to conduct a systematic review and meta-analysis to explore the optimal therapies for refractory MG.Method: Correlative studies were performed through a search in PubMed, Cochrane Library, and Embase databases., The primary efficacy endpoint was the change of the MG-ADL score from baseline to week 26. Ravulizumab was more effective than placebo in improving MG-ADL (−3.1 vs 1.4) …, The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half century, including substantial reductions in mortality and …, The primary outcome measure was the occurrence of treatment-refractory MG. We defined treatment-refractory myasthenia gravis at the earliest 2 years after diagnosis as soon as the following conditions were met: 1. Persistent moderate to severe myasthenic symptoms (i.e., ≥ MGFA class III) for the last 12 months OR. 2., 17 февр. 2018 г. ... Rituximab in Treatment-Refractory Myasthenia Gravis - Download as a PDF or view online for free., Treatment of Patients With Severe Weakness and Refractory Myasthenia Gravis. When treating patients with new-onset MG with severe weakness, it is preferable to start with IVIg, efgartigimod, or plasma exchange, followed by maintenance immunosuppressants., Turkey gravy is not hard to make, but that does not stop some people from feeling very anxious about it. This actually makes sense to me: If you’ve never taken a thin liquid and made it thick, the process is quite mystifying. In reality tho..., The humanized monoclonal antibody eculizumab (Soliris ®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. , Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive ..., Myasthenia Gravis (MG) is a chronic autoimmune disease (AID) with a prevalence of 1–2 per 10.000 [1]. The clinical hallmark is fluctuating weakness of striated muscles with antibodies directly affecting the neuromuscular junction. In approximately 85% of patients, the initial presenting symptoms are asymmetric ptosis and/or diplopia. Approximately 80% of initially ocular MG …, Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. ... Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord NMD. 2017; 27:565–568. doi: …, Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response. However, clinical stabilization is often reached at the cost of many ... , SYSTEMATIC REVIEW article Front. Neurol., 13 October 2021 Sec. Neuromuscular Disorders and Peripheral Neuropathies Volume 12 - 2021 | https://doi.org/10.3389/fneur.2021.736190 Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis, Oct 13, 2016 · Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab Abstract. Introduction: Myasthenia gravis (MG) is an antibody mediated autoimmune neuromuscular disorder characterized... Introduction. Myasthenia gravis (MG) is a relatively rare antibody-mediated neurologic ... , Introduction: Approximately 10–20% of patients WITH myasthenia gravis (MG) are refractory to conventional immunotherapies. The purpose of this study was to conduct a systematic review and meta-analysis to explore the optimal therapies for refractory MG.Method: Correlative studies were performed through a search in PubMed, Cochrane Library, and Embase databases., Traditionally, patients with myasthenia gravis have been treated with pyridostigmine, corticosteroids, immunosuppressants (eg, azathioprine and mycophenolate mofetil), …, Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. Methods: We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with ..., Myasthenia Gravis (MG) is a rare autoimmune disorder that targets the neuromuscular junction (NMJ). It is caused by B-cell activation with subsequent production of autoantibodies targeting different proteins of the postsynaptic endplate. About 80–90% of patients have antibodies directed against the nicotinic acetylcholine receptor (AChR ..., Myasthenia Gravis (MG) is a chronic autoimmune disease (AID) with a prevalence of 1–2 per 10.000 [1]. The clinical hallmark is fluctuating weakness of striated muscles with antibodies directly affecting the neuromuscular junction. In approximately 85% of patients, the initial presenting symptoms are asymmetric ptosis and/or diplopia. Approximately 80% of initially ocular MG …, Therapeutic options for refractory MG are reviewed in detail separately. (See "Chronic immunotherapy for myasthenia gravis", section on 'Refractory disease'.), Our patient has had a refractory course with respect to myasthenia gravis. Other options for treatment of refractory myasthenia gravis include rituximab, high-dose cyclophosphamide and eculizumab . Given our patient’s progression of both autoimmune diseases, we explored the possibility of hematopoietic stem cell transplant (HSCT)., Myasthenia gravis (MG) is a chronic rare autoimmune disease characterized by severe muscle weakness and caused by the inhibition of neuromuscular transmission due to the binding of autoantibodies at the neuromuscular junction and subsequent complement-mediated destruction of the end-plate region. The prevalence of MG has been estimated as ..., SYSTEMATIC REVIEW article. Front. Neurol., 13 October 2021. Sec. Neuromuscular Disorders and Peripheral Neuropathies. Volume 12 - 2021 | …, Refractory Myasthenia Gravis. Myasthenia gravis (MG) is an autoimmune condition in which the body mistakenly attacks itself. In MG, the way nerves and muscles communicate is affected. MG is treated with different drugs that either improve this communication or slow down the incorrect immune response. , All the above-mentioned favorable outcomes of rituximab in refractory myasthenia gravis patients have widened the options for treatment of refractory myasthenia gravis; they have also demonstrated that RTX could improve patients' quality of life by decreasing dose-related adverse effects and sustaining remission [10,12-17]. Even though RMG ..., Patients Who Achieved Myasthenia Gravis Foundation of America Post-intervention Status of Improved or Minimal Manifestations at REGAIN (Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia Gravis) Weeks 4, 12, and 26, and Open-Label Study Weeks 26, 52, 78, 104, and 130